Minulet (Ethinylestradiol, Gestodene)

Minulet, a combined oral contraceptive, is indicated for hormonal contraception and related menstrual management.

• Contraception: Prevents unintended pregnancy by suppressing ovulation.
• Menstrual cycle regulation: Provides predictable withdrawal bleeding and reduces cycle irregularities.
• Acne improvement: May decrease acne associated with androgen excess in women.

• Minulet contains ethinylestradiol and gestodene, which bind to estrogen and progestogen receptors respectively. The estrogen component suppresses the hypothalamic‑pituitary‑gonadal axis, reducing follicle‑stimulating hormone (FSH) release, while the progestogen component blocks luteinizing hormone (LH) surge, together preventing ovulation. Additional actions include thickening cervical mucus and inducing endometrial changes that hinder implantation.

Like all hormonal contraceptives, Minulet may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Breast tenderness: swelling or discomfort.
• Headache: occasional tension‑type headache.
• Spotting or breakthrough bleeding: irregular bleeding between periods.
• Weight gain: slight increase in body weight.
• Mood changes: irritability or emotional fluctuations.

Serious or Rare Side Effects

• Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism.
• Arterial thrombosis: stroke or myocardial infarction.
• Severe hypertension: sudden rise in blood pressure.
• Liver tumor: benign hepatic adenoma.
• Allergic reaction: rash, swelling, or anaphylaxis.
• Severe depression or suicidal thoughts.

Before prescribing Minulet, clinicians should evaluate several safety considerations to minimize risk.

• Contraindicated in pregnancy: product is category X and must not be used.
• Avoid in smokers over 35: increased risk of thromboembolic events.
• Assess cardiovascular risk: not suitable for women with history of thrombosis or uncontrolled hypertension.
• Screen for estrogen‑dependent tumors: use with caution in known breast or endometrial cancer.
• Monitor liver function: caution in patients with hepatic impairment.
• Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Minulet can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid)

• Enzyme‑inducing antiepileptics (e.g., carbamazepine, phenytoin): markedly reduce contraceptive effectiveness.
• Rifampin and other strong CYP3A4 inducers: lower plasma levels of both hormones.
• Combined estrogen therapy: may increase risk of estrogen‑related adverse events.
• Anticoagulants (e.g., warfarin): potential for altered clotting risk.
• Protease inhibitors (e.g., ritonavir): may affect hormone metabolism.

Moderate Interactions (Monitor Closely)

• Antibiotics such as tetracycline or metronidazole: may slightly decrease contraceptive reliability.
• St. John’s Wort: can reduce hormone levels, requiring backup contraception.
• Antifungal agents (e.g., ketoconazole): may increase hormone concentrations.
• Antihypertensive drugs: hormonal changes can influence blood pressure control.